Shares of Intra-Cellular Therapies (ITCI) have gained 3.6% over the past four weeks to close the last trading session at $71.56, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $93.13 indicates a potential upside of 30.1%.The mean estimate comprises 15 short-term price targets with a standard deviation of $14.69. While the lowest estimate of $65 indicates a 9.2% decline from the ...